NFKB1 and breast carcinoma: RESV‐loaded MSN particles inhibited breast cancer progression more effectively than RESV alone by hindering the NF‐κB signaling pathway, indicating that MSN‐RESV can be used as adjuvant management for breast cancer with an improved efficacy.